晨光生物
(300138)
| 流通市值：43.66亿 | | | 总市值：52.95亿 |
| 流通股本：3.98亿 | | | 总股本：4.83亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,716,472,687.32 | 6,994,192,786.23 | 5,225,428,968.08 | 3,490,929,927.87 |
| 营业收入 | 1,716,472,687.32 | 6,994,192,786.23 | 5,225,428,968.08 | 3,490,929,927.87 |
| 二、营业总成本 | 1,605,425,014.2 | 6,868,044,529.72 | 5,127,064,914.93 | 3,408,448,437.38 |
| 营业成本 | 1,473,470,723.79 | 6,437,297,116.3 | 4,840,074,864.79 | 3,201,829,609.02 |
| 税金及附加 | 7,020,357.25 | 19,180,239.35 | 13,344,104.62 | 8,801,877.36 |
| 销售费用 | 12,345,145.41 | 50,140,684.42 | 33,687,842.99 | 26,065,300.95 |
| 管理费用 | 43,655,262.73 | 160,557,194.85 | 113,593,225.02 | 79,586,672.47 |
| 研发费用 | 41,738,594.25 | 128,602,770.25 | 72,436,744.27 | 47,913,591.56 |
| 财务费用 | 27,194,930.77 | 72,266,524.55 | 53,928,133.24 | 44,251,386.02 |
| 其中:利息费用 | 33,854,519.77 | 114,417,669.76 | 83,833,064.72 | 65,144,695.63 |
| 其中:利息收入 | 9,565,581.63 | 40,574,981.05 | 32,025,126.67 | 19,046,226.89 |
| 加:公允价值变动收益 | 1,257,597.41 | -5,111,280.46 | 1,121,316.72 | -6,447,474.73 |
| 加:投资收益 | 12,924,632.22 | 17,787,444.36 | 7,271,875 | 15,988,000.75 |
| 资产处置收益 | 4,034,011.68 | 4,887,839.58 | - | - |
| 资产减值损失(新) | -7,922,514.3 | -95,164,207.13 | -82,674,966.04 | -2,369,527.74 |
| 信用减值损失(新) | 3,078,566.4 | -3,809,661.36 | -312,056.38 | -700,644.32 |
| 其他收益 | 5,393,676.59 | 61,297,185.21 | 36,490,505.82 | 18,859,431.25 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 129,813,643.12 | 106,035,576.71 | 60,260,728.27 | 107,811,275.7 |
| 加:营业外收入 | 1,626,364.56 | 38,821,823.51 | 17,378,169.62 | 6,931,437.38 |
| 减:营业外支出 | 156,682.09 | 37,912,075.51 | 3,286,257.93 | 648,776.56 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 131,283,325.59 | 106,945,324.71 | 74,352,639.96 | 114,093,936.52 |
| 减:所得税费用 | 20,095,937.65 | 28,988,211.22 | 29,112,483.18 | 20,303,233.88 |
| 六、净利润 | 111,187,387.94 | 77,957,113.49 | 45,240,156.78 | 93,790,702.64 |
| 持续经营净利润 | 111,187,387.94 | 77,957,113.49 | 45,240,156.78 | 93,790,702.64 |
| 归属于母公司股东的净利润 | 109,480,325.98 | 94,049,622.14 | 62,605,888.08 | 99,834,623.94 |
| 少数股东损益 | 1,707,061.96 | -16,092,508.65 | -17,365,731.3 | -6,043,921.3 |
| (一)基本每股收益 | 0.23 | 0.18 | 0.12 | 0.19 |
| (二)稀释每股收益 | 0.23 | 0.18 | 0.12 | 0.19 |
| 八、其他综合收益 | -807,209.72 | 3,336,226.69 | -6,507,503.31 | 2,758,363.21 |
| 归属于母公司股东的其他综合收益 | -807,209.72 | 3,336,226.69 | -6,507,503.31 | 2,758,363.21 |
| 九、综合收益总额 | 110,380,178.22 | 81,293,340.18 | 38,732,653.47 | 96,549,065.85 |
| 归属于母公司股东的综合收益总额 | 108,673,116.26 | 97,385,848.83 | 56,098,384.77 | 102,592,987.15 |
| 归属于少数股东的综合收益总额 | 1,707,061.96 | -16,092,508.65 | -17,365,731.3 | -6,043,921.3 |
| 公告日期 | 2025-04-26 | 2025-04-08 | 2024-10-26 | 2024-08-27 |
| 审计意见(境内) | | 标准无保留意见 | | |